Dear Editor, Chlorpheniramine (CPM) is a first generation histaminereceptor-1 antagonist registered in the World Health Organization Model List of Essential Medicines [1] . Due to its moderate degree of sedative effects, it is frequently used as a component of compound preparations for symptomatic treatment of common cold and influenza symptoms.
CPM shows pronounced interindividual variability in pharmacokinetics, with an elimination half-life ranging from 2 to 43 h because of individual hepatic metabolism and the different activity of the involved cytochrome CYP2D6, which has a pronounced genetic polymorphism [2, 3] . Besides this mechanism, there are still unknown metabolic pathways that are involved in the disposition of CPM in humans [2] . CPM and its metabolites are excreted in a pH-dependent fashion in the urine with individual excretion dosages of unchanged CPM ranging from 0 to 34% [1, 4] (see also drug information).
A 40-year-old woman (63 kg body weight; BMI 21 kg/m 2 ; Caucasian), otherwise healthy, was initially admitted to a primary care hospital after torsades de pointes tachycardia (TdP) that necessitated cardiopulmonary resuscitation. Repeated TdP was monitored there (Fig. 1a) in the first 24 h after administration and was treated successfully by magnesium infusions. At the second day after onset of TdP, the patient was referred to the cardiology department of the University of Cologne for further diagnostics. Laboratory values, including creatinine, were in normal ranges except for mildly elevated alanine aminotransferase and aspartate aminotransferase. The main pathological finding was detected by the retrospective evaluation of the documented electrocardiogram (ECG) during the inhospital observed TdP tachycardia: the corrected QT interval (QTc) using Bazett's formula was prolonged up to 524 ms (Fig. 1a) . Therefore the diagnosis of long-QT syndrome (LQTS) was made. The ECGs documented in our hospital revealed a borderline QTc of 440 ms (Fig. 1b) . All other diagnostic procedures were normal including coronary angiogram, ventriculography, and complete invasive electrophysiological testing.
The patient was on no permanent medication, denied abusing any other substances, was completely unremarkable on physical examination, and had no prior history of cardiac arrhythmias. She smoked regularly up to 5 cigarettes a day, drank small amounts of wine and had suffered from a common cold for some days, which she self-medicated with a compound medication taking two capsules three times a day. She had stopped self-medication the evening before the event. Each capsule contained 200 mg of acetaminophen, 150 mg of ascorbic acid, 25 mg of caffeine, and 2.5 mg of CPM. In animal experiments, CPM has been shown to present a dosedependent block of the delayed rectifier potassium channel I Kr , and to lengthen the action potential, slow cardiac repolarization, and prolong the QTc interval [5] [6] [7] [8] [9] . The CPM-like drug diphenhydramine also significantly prolonged the QTc interval in healthy volunteers and in patients with coronary heart diseases [10] .
The coincidence between drug intake and prolongation of the QT interval in our patient is highly suggestive of CPM-induced TdP. One may speculate that the patient is a poor metabolizer with respect to CYP2D6 activity, which might have contributed to an extensive exposure, however, the patient did not agree to genotyping. The almost normal QTc interval 2 days after cessation of drug intake supports the causal link to CPM since serum concentration may have been decreased considerably at this time even in case of a long elimination half-life as expected for poor metabolizers.
In 1978 the putative first case of CPM-induced TdP was reported. A young women on long-term thioridazine medication took a compound preparation containing CPM (Contac C®) and died due to ventricular arrhythmia [11] .
The authors assumed the combination of the neuroleptic with ephedrine to be fatal, but we speculate that CPM might have played a more prominent role inducing fatal tachycardia than suspected. Indeed, thioridazine is both a substrate and inhibitor of CYP2D6, and also prolongs the QTc interval [12] [13] [14] . Concomitant medication with the two drugs thus may have resulted in a drug-drug interaction at both the pharmacokinetic and the pharmacodynamic level.
To be on the safe side, in our patient a cardioverter defibrillator was implanted, and we recommended that she avoid any medications known to interact with the QT interval (see list at www.azcert.org) and drugs containing CPM. Certainly this report is limited owing to the missing evaluation of the initial drug concentration. Thus we cannot clarify the exact causal link between CPM intake and the occurrence of TdP. In particular, the underlying cold of the patient might have been jointly responsible for the QT prolongation [15] [16] [17] .
Nonetheless it is important to report this case because several levels of evidence suggest that second generation antihistamines interfere with the QT interval while CPM might be overlooked [18, 19] . At the same time, CPM is used worldwide in compound preparations, usually as an over-the-counter drug and available for self-medication without the need for a prescription. In particular, patients with known LQTS should avoid such compounds containing antihistamines until their harmlessness in these highrisk patients has been proven.
